OPKO Health to Report First Quarter 2020 Financial Results on May 6, 2020
April 30 2020 - 04:05PM
OPKO Health, Inc. (NASDAQ: OPK) plans to report
operating and financial results for the three months ended March
31, 2020, as well as discuss financial guidance, after the close of
the U.S. financial markets on Wednesday, May 6, 2020.
CONFERENCE CALL & WEBCAST
INFORMATION
OPKO’s senior management will provide a business
update and discuss results in greater detail in a conference call
and live audio webcast at 4:30 p.m. Eastern time on Wednesday, May
6, 2020. The conference call dial-in and webcast information is as
follows:
DOMESTIC DIAL-IN:INTERNATIONAL DIAL-IN:PASSCODE:WEBCAST: |
|
(877) 783-8475(614) 999-18279095275OPKO 1Q20 Results Conference
Call |
|
|
|
For those unable to participate in the live
conference call or webcast, a replay will be available beginning
approximately two hours after the close of the conference call. To
access the replay, dial 855-859-2056 or 404-537-3406. The replay
passcode is 9095275. The replay can be accessed for a period of
time on OPKO’s website at OPKO 1Q20 Results Conference Call.
About OPKO Health
OPKO Health is a diversified healthcare company.
In diagnostics, its BioReference Laboratories is one of the
nation's largest full-service clinical laboratories; GeneDx is a
rapidly growing genetic testing business; the 4Kscore® test is used
to assess a patient’s individual risk for aggressive prostate
cancer following an elevated PSA and to help decide about next
steps such as prostate biopsy; Claros® 1 is a point-of-care
diagnostics platform with a total PSA test approved by the
FDA. In our pharmaceutical pipeline, RAYALDEE is our first
pharmaceutical product to be marketed. OPK88003, a
once-weekly oxyntomodulin for type 2 diabetes and obesity -
reported positive data from a Phase 2 clinical trial. It’s
among a new class of GLP-1/glucagon receptor dual agonists.
OPK88004, a SARM (selective androgen receptor modulator) is
currently being studied for various potential indications. The
Company’s most advanced product utilizing its CTP technology, a
once-weekly human growth hormone for injection, successfully met
its primary endpoint and key secondary endpoints in a Phase 3 study
and is partnered with Pfizer. OPKO also has research, development,
production and distribution facilities abroad.
Contacts:
LHA Investor RelationsYvonne
Briggs, 310-691-7100ybriggs@lhai.comorBruce Voss, 310-691-7100
bvoss@lhai.com
Opko Health (NASDAQ:OPK)
Historical Stock Chart
From Feb 2024 to Mar 2024
Opko Health (NASDAQ:OPK)
Historical Stock Chart
From Mar 2023 to Mar 2024